Table 1 Samples Characteristics
Parameter Characteristic
Age Year 35
35 - 40 41
– 50 51
– 60 60
Menopausal Status Premenopause
Postmenopause 46.16±10.42
8 12.90 12 19.35
20 32.25 11 17.74
11 17.74
4369.35 1930.64
Tumor Diametercm 8.66±4,06
Histopathology Type IDC
6198.38 ILC
11.61 Grade
I 69.67
II 1829.03
III 3861.29
4.2 Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer
Chemoterapy Response
Response
5 10
15 20
25 30
35 40
45
No Response Response
C a
s e
s 70,96
29,03
Figure 1 Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer
n = 62. Figure 1 showed that from 62 samples after 3 cycles of NAC, 44 samples
70.96 had negative NAC response and 18 samples 29.03 had positive NAC response.
Figure 2 Positive Response Types towards NAC: PR;
cCR; pCR
Figure 2 showed positive type responses toward NAC, from 18 samples who showed positive response, 16 samples 25.80 had partial response PR,
while 2 samples 3.23 had clinical complete response cCR, which later were proven to be pathological complete response pCR.
4.3
mRNA Caspase-3 Level Decrease Correlation with Negative Chemotherapy Response
Prechemotherapy and postchemotherapy of mRNA Caspase-3 level were measured to determine the difference of mRNA Caspase-3 levels. Data is shown
in Table 2.
Table 2 mRNA caspase-3 Level Decrease in LABC Patients
Parameter prechemotherapy
Postchemotherapy p
mRNA caspase-3 12.51±3.03
11.64±3.13 0,611
Positive Response Types towards NAC
5 10
15 20
PR cCR pCR
K a
s u
s
Response
5 10
15 20
PR cCR pCR
K a
s u
s K
a s
u s
3,23 C
a s
e s
5 10
15 20
PR cCR pCR
25,80
pgmL p
0.064 0.084
mRNA caspase-3 Level DecreasepgmL
0.87±1.96 significant for normal distribution p 0.05
significant for variance homogenity p 0.05
Data from Table 2 were analyzed by t-paired test to determine the difference of mRNA Caspase-3 level prechemotherapy and postchemotherapy. T-
paired test result showed a normal and homogeneous data. There was a significant decrease of mRNA Caspase-3 level 0.87±1.96 pgmL, p 0.05.
Phi and Cramer’s V Test was performed to determine the role of post 1st cycle NAC mRNA Caspase-3 level decrease as a negative chemotherapy response
risk in LABC. Data transformation from numeric to categorical was performed. Analysis results is shown in Table 3.
Table 3 Post 1st cycle NAC mRNA Caspase-3 level decrease as a negative chemotherapy
response risk in LABC
Parameter Response
Total Negative
Positive Decreased
Level Yes
31 6
37 No
13 12
25 Total
44 18
62 p
= 0.007; RR = 4.769; CI95 1.473 – 15.438.
Phi and Cramer’s V Correlation Test showed post 1st cycle NAC mRNA
Caspase-3 level decrease as a negative chemotherapy response risk in LABC r=0.343; p=0.007. The Relative Risk RR was 4.796 1.473-15.438; CI 95.
4.4 Apoptosis Index Level Decrease Correlation with Chemotherapy Response Risk
